美股市場個股詳情
JAZZ 爵士製藥
- 111.550
- +0.120+0.11%
收盤價 11/06 16:00 (美東)
- 113.996
- +2.446+2.19%
盤後 19:07 (美東)
68.89億總市值18.91市盈率TTM
114.120最高價110.630最低價82.17萬股成交量113.050今開111.430昨收9186.72萬成交額1.37%換手率18.29市盈率(靜)6175.35萬總股本134.17052周最高1.83市淨率66.89億流通值99.06052周最低--股息TTM5996.59萬流通股194.730歷史最高--股息率TTM3.13%振幅0.515歷史最低111.794平均價1股每手
關於爵士製藥公司
Jazz Pharmaceuticals是一家位於愛爾蘭的生物製藥公司，主要專注於睡眠障礙和腫瘤的治療。Jazz在神經科學和腫瘤適應症領域有9種獲批藥物;其產品組合包括治療嗜睡症的Xyrem和Xywav，治療轉移性小細胞肺癌的Zepzelca，治療急性淋巴細胞白血病的Rylaze，以及治療急性髓細胞白血病的Vyxeos。2021年5月，Jazz收購了GW Pharmaceuticals，獲得了其主要產品Epidiolex，用於治療嚴重、罕見類型的癲癇。
公司介紹
公司代碼JAZZ
公司名稱爵士製藥
上市日期2007/06/01
發行價格18.00
成立日期2005
CEOMr. Bruce C. Cozadd
所屬市場納斯達克
員工數量2800
年結日12-31
公司地址Waterloo Exchange,Waterloo Road,5th Floor
城市Dublin
省份都柏林
國家愛爾蘭共和國
郵編4
電話353-1-634-7800
董事高管
-
姓名
- 職務
- 年薪
-
Bruce C. Cozadd
- Chairman of the Board and Chief Executive Officer
- 1534.12萬
-
Patricia Carr
- Senior Vice President and Chief Accounting Officer
- 140.10萬
-
Neena M. Patil
- Executive Vice President and Chief Legal Officer
- 387.74萬
-
Renee D. Gala
- President and Chief Operating Officer
- 543.44萬
-
Philip L. Johnson
- Executive Vice President and Chief Financial Officer
- --
-
Dr. Robert Iannone, M.D.
- Executive Vice President and Global Head of Research and Development
- 497.91萬
-
Samantha Pearce
- Senior Vice President, Europe and International
- --
-
Liz Henderson
- Senior Vice President, Technical Operations
- --
-
Anne O'Riordan
- Independent Director
- 52.38萬
-
Seamus C. Mulligan
- Independent Director
- 53.13萬
-
Laura J. Hamill
- Independent Director
- --
-
Patrick Thomas Kennedy
- Independent Director
- --
-
Jennifer E. Cook
- Independent Director
- 53.38萬
-
Heather Ann McSharry
- Independent Director
- 54.38萬
-
Rick E. Winningham
- Lead Independent Director
- 57.13萬
-
Dr. Norbert G. Riedel,PhD
- Independent Director
- 53.38萬
-
Dr. Mark D. Smith, M.D.
- Independent Director
- 52.13萬
-
Patrick G. Enright
- Independent Director
- 52.63萬
-
Kenneth W. O'Keefe
- Independent Director
- 51.38萬
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
升跌幅
暫無數據